Messenger RNAs (mRNAs) represent a fast-emerging class of biotherapeutics. They hold considerable promise, offering new opportunities for targeted treatment and flexible manufacturing, as was recently demonstrated by the rapid development of mRNA-based COVID -19 vaccines. In recent years, we at Lonza have amassed considerable expertise in the commercial manufacturing of mRNA and its encapsulation in Lipid Nanoparticles (LNP) at cGMP quality.
You may also be interested in:
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center